Uenami Takeshi, Hosono Yuki, Ishijima Mikako, Kanazu Masaki, Akazawa Yuki, Yano Yukihiro, Mori Masahide, Yamaguchi Toshihiko, Yokota Soichiro
Department of Thoracic Oncology, Toneyama National Hospital, Osaka, Japan.
Lung Cancer. 2017 Jul;109:42-44. doi: 10.1016/j.lungcan.2017.04.019. Epub 2017 Apr 27.
Nivolumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for treating patients with late-stage non-small-cell lung cancer. Immune checkpoint inhibitors such as nivolumab induce various kinds of immune-related adverse events, including vitiligo. Vitiligo has been reported in patients with melanoma but not lung cancer. We describe a 75-year-old man with lung adenocarcinoma, stage 4 with pleural and pericardial effusion, that progressed after first-line chemotherapy. Subsequently, he was treated with nivolumab as second-line therapy. After 6days of administering nivolumab, he developed vitiligo suddenly on the trunk of his body. Except for vitiligo, his physical examination was normal, and treatment with nivolumab was well tolerated. Therefore, this treatment was continued without further development or expansion of vitiligo. A computed tomography scan showed a reduction in the size of the lung nodule and stabilization of the pleural and pericardial effusion. This is the first case of vitiligo associated with the use of nivolumab in a patient with lung adenocarcinoma.
纳武单抗是一种抗程序性细胞死亡蛋白1单克隆抗体，对治疗晚期非小细胞肺癌患者有效。像纳武单抗这样的免疫检查点抑制剂会引发各种免疫相关不良事件，包括白癜风。白癜风在黑色素瘤患者中已有报道，但在肺癌患者中未见报道。我们描述了一名75岁男性，患有肺腺癌，IV期伴胸腔和心包积液，一线化疗后病情进展。随后，他接受纳武单抗作为二线治疗。使用纳武单抗6天后，他的躯干突然出现白癜风。除白癜风外，他的体格检查正常，对纳武单抗治疗耐受性良好。因此，继续该治疗，白癜风未进一步发展或扩大。计算机断层扫描显示肺结节大小缩小，胸腔和心包积液稳定。这是首例与纳武单抗使用相关的肺腺癌患者发生白癜风的病例。
